Sulfur (SⅥ)-containing heterocyclic hybrids as antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA) and its SAR

• Published in: Bioorganic chemistry Vol. 145; p. 107241
• Main Authors: Verma, Santosh Kumar, Rangappa, Shobith, Verma, Rameshwari, Xue, Fan, Verma, Shekhar, Sharath Kumar, Kothanahally S., Rangappa, Kanchugarakoppal S.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2024
• Subjects: Antibacterial agents; Azoles; MRSA; SAR; Sulfur (SVI)-hybrids; NR; SAR; WTA; HTS; MIC; Sulfur (SVI)-hybrids; SASF; ESKAPE; Antibacterial agents; MBC; SuFEx; SD; Azoles; DFT; S. aureus; PABA; MRSA; LTA; DOC; ESF; MDR; PK; ALH; Sulfur (S(VI))-hybrids
• ISSN: 0045-2068; 1090-2120
• DOI: 10.1016/j.bioorg.2024.107241

[Display omitted] •Sulfur (SⅥ)-containing heterocyclic hybrids displayed potent antibacterial activity against tested MRSA strains.•Structure-activity relationship is explained in detail.•Sulfur (SⅥ)-containing heterocyclic hybrids exhibited excellent antibacterial activity with different action of mechanism.•Sulfur (SⅥ)-containing heterocyclic hybrids acts as antibiofilm agents, DNA binding agents, enzyme inhibitors and showed synergistic effect with antibiotics. The discovery of new small molecule-based inhibitors is an attractive field in medicinal chemistry. Structurally diversified heterocyclic derivatives have been investigated to combat multi-drug resistant bacterial infections and they offers several mechanism of action. Methicillin-resistant Staphylococcus aureus (MRSA) is becoming more and more deadly to humans because of its simple method of transmission, quick development of antibiotic resistance, and ability to cause hard-to-treat skin and filmy diseases. The sulfur (SVI) particularly sulfonyl and sulfonamide based heterocyclic moieties, have found to be good anti-MRSA agents. The development of new nontoxic, economical and highly active sulfur (SVI) containing derivatives has become hot research topics in drug discovery research. Presently, more than 150 FDA approved Sulfur (SVI)-based drugs are available in the market, and they are widely used to treat various types of diseases with different therapeutic potential. The present collective data provides the latest advancements in Sulfur (SVI)-hybrid compounds as antibacterial agents against MRSA. It also examines the outcomes of in-vitro and in-vivo investigations, exploring potential mechanisms of action and offering alternative perspectives on the structure–activity relationship (SAR). Sulfur (SVI)-hybrids exhibits synergistic effects with existing drugs to provide antibacterial action against MRSA